A clinical trial does not begin when the first participant receives an investigational treatment.
Long before that moment, extensive scientific,
regulatory, ethical and operational preparation must take place.
The protocol must be finalized. Countries and sites
must be selected. Regulatory and ethics requirements must be addressed.
Contracts must be negotiated. Investigational products must be available.
Investigators and site teams must be trained. Critical systems must be ready.
Only then can recruitment and enrolment proceed
appropriately.
This period is commonly described as clinical trial
start-up.
For sponsors, it is one of the most consequential
stages of clinical development.
A delay during start-up can affect recruitment
forecasts, operational budgets, country contributions and overall development
timelines.
More importantly, inadequate preparation can create
risks to participant protection and data reliability.
The objective is therefore not simply to activate
sites quickly.
It is to activate sites efficiently, compliantly and
with the capabilities needed to deliver the protocol.
1. Study Start-Up Begins With Protocol Readiness
A protocol is the scientific and operational
foundation of a clinical trial.
It defines the research objectives, design,
population, interventions, assessments, endpoints and statistical
considerations.
But a scientifically valid protocol is not
automatically an operationally feasible protocol.
Before initiating sites, sponsors should evaluate
whether:
- Eligibility criteria can be consistently
interpreted.
- Required assessments are available at intended
sites.
- Visit schedules are realistic.
- Safety assessments are operationally achievable.
- Endpoint measurements are standardized.
- Investigational product requirements can be
supported.
- Participants can reasonably comply with study
procedures.
ICH E8(R1) emphasizes building quality into clinical
studies during the design stage, including identifying factors critical to
participant protection and reliable results [1].
This means start-up readiness begins before regulatory
submission.
A protocol that cannot be implemented reliably will
not become feasible simply because more sites are activated.
2. Country Selection Is a Strategic Decision
In multinational clinical trials, country selection
should consider much more than patient population size.
Sponsors need to assess:
- Disease epidemiology and patient accessibility
- Local standard of care
- Investigator and site capabilities
- Competing clinical trials
- Regulatory and ethics pathways
- Expected start-up timelines
- Investigational product import requirements
- Laboratory and diagnostic infrastructure
- Language and documentation requirements
- Recruitment contribution within the planned study
window
A country with a substantial patient population may
still contribute relatively little if site activation occurs late.
Conversely, a smaller country with experienced
investigators and efficient start-up may provide meaningful enrollment.
Country feasibility should therefore be linked to the
overall clinical development strategy.
3. Site Feasibility Must Test Operational Reality
An investigator expressing interest in a protocol is
not the same as a site being ready to deliver it.
A comprehensive feasibility assessment should
evaluate:
Patient access: Does the site manage a
sufficient number of potentially eligible participants?
Investigator capacity: Can the
principal investigator provide adequate oversight?
Site staffing: Are research nurses, CRCs and
backup personnel available?
Facilities: Can required examinations, laboratory procedures and
treatment activities be performed?
Competition: Are other studies targeting the same population?
Recruitment: Are enrollment forecasts supported by realistic
assumptions?
Quality: Does the site have the systems and experience needed
to generate reliable data?
The purpose is to identify sites capable of delivering
the protocol, not merely sites willing to participate.
4. Regulatory and Ethics Submissions Require Early
Planning
Before trial initiation, sponsors must satisfy
applicable regulatory and independent ethics review requirements.
The precise pathway varies across jurisdictions.
In the European Union and European Economic Area, the
Clinical Trials Regulation provides a harmonized framework supported by the
Clinical Trials Information System (CTIS) [2,3].
Other countries have their own regulatory and ethics
requirements.
Sponsors should map:
- Required applications and supporting documents
- Regulatory authority responsibilities
- Ethics committee requirements
- Submission dependencies
- Review timelines
- Responses to questions
- Approval conditions
- Required notifications before recruitment
Regulatory approval and ethics approval should not be
treated as interchangeable.
Both are essential components of the applicable
authorization framework.
5. Contracting and Budget Negotiation Can Determine
Activation Timelines
A site may be scientifically suitable and have the
necessary approvals but remain unable to begin recruitment because contractual
arrangements are incomplete.
Clinical Trial Agreements may address:
- Responsibilities of the sponsor and institution
- Study budgets and payment arrangements
- Insurance and indemnification
- Confidentiality
- Data protection
- Publication rights
- Record retention
- Monitoring and audit access
Contracting often involves several institutional
departments.
Where legally and operationally appropriate,
contracting and other start-up workstreams should progress in parallel.
However, no activity should begin before the
approvals, agreements and conditions required for that activity are in place.
6. Investigational Product Readiness Is Essential
Site activation is not meaningful if the
investigational product cannot be supplied appropriately.
Sponsors need to coordinate:
- Manufacturing and packaging
- Labelling
- Import requirements
- Shipment and distribution
- Temperature control
- Storage conditions
- Accountability procedures
- Randomization and supply systems
- Resupply arrangements
The site must also have appropriately trained
personnel and suitable facilities for handling the investigational product.
Supply-chain readiness should be assessed before the
intended recruitment date.
7. Essential Documents and Systems Must Be Ready
Clinical trial start-up involves establishing the
records and systems needed to demonstrate that the trial is appropriately
authorized, organized and controlled.
Depending on the study, this may include:
- Investigator qualifications and training records
- Delegation documentation
- Approved protocol and amendments
- Ethics and regulatory approvals
- Investigator's Brochure
- Site-specific documents
- Laboratory certifications and reference ranges
- Monitoring arrangements
- EDC access
- Safety reporting instructions
- Trial Master File processes
ICH E6(R3) emphasizes essential records and
appropriate management of computerized systems and data throughout the trial
lifecycle [4].
The objective is not to accumulate documents.
It is to ensure that responsibilities, decisions and
important activities are traceable.
8. Site Initiation Is More Than a Training Meeting
The Site Initiation Visit (SIV), or an equivalent
documented initiation process, is a critical readiness milestone.
The site team should understand:
- Study objectives and design
- Eligibility criteria
- Informed consent procedures
- Investigational treatment administration
- Safety assessment and reporting
- Protocol-specific procedures
- Endpoint assessments
- Data entry and query resolution
- Investigational product accountability
- Escalation pathways
Training must be relevant to the individual's
delegated responsibilities.
A site should not be considered ready merely because
an initiation meeting has occurred.
Readiness means the site can perform the required
activities appropriately.
9. Site Activation and First Patient In Are Different
Milestones
A site may be activated but still take weeks or months
to enroll its first participant.
Potential reasons include:
- Limited access to eligible patients
- Competing studies
- Patient referral delays
- Restrictive eligibility criteria
- Participant reluctance
- Diagnostic or screening requirements
- Changes in clinical practice
Sponsors should therefore track both activation and
recruitment performance.
Useful milestones include:
Regulatory submission → Authorization → Site readiness
→ Activation → First patient screened → First patient enrolled
Each milestone answers a different operational
question.
10. Why Start-Up Delays Should Be Analyzed, Not Simply
Reported
A dashboard showing that a site is delayed provides
limited value without explaining the reason.
Sponsors should distinguish between:
Regulatory delays
Ethics delays
Contracting delays
Document readiness
Training gaps
IMP supply
Technology readiness
Site capacity
Each requires a different intervention.
Opening additional sites will not necessarily resolve
a systemic contracting problem.
Similarly, increasing CRA resources may not correct an
import restriction.
Effective start-up management depends on identifying
the actual bottleneck.
11. The Sponsor's Start-Up Readiness Checklist
Before declaring a site ready, the study team should
be able to answer:
- Have applicable regulatory and ethics
requirements been satisfied?
- Are necessary agreements and budgets finalized?
- Is the site adequately staffed and trained?
- Are essential records complete and appropriately
controlled?
- Are investigational products and required
materials available?
- Are required systems functional and accessible?
- Are safety reporting and escalation procedures
understood?
- Can the site perform critical protocol
procedures?
- Are unresolved risks documented and appropriately
managed?
- Is there a clear decision authorizing site
activation?
These questions provide a practical framework for
readiness assessment.
The Agile Clinical Trendz Perspective
At Agile Clinical Trendz, we believe effective
study start-up requires integrated planning across regulatory affairs, clinical
operations, site management, contracts, supply, quality, safety and technology.
The strongest start-up models provide:
Central visibility
Local operational expertise
Clear ownership
Realistic timelines
Early risk identification
Documented readiness decisions
For sponsors, the objective should not be the largest
number of activated sites in the shortest possible period.
It should be the activation of a capable,
appropriately prepared site network that can recruit participants safely and
generate reliable clinical evidence.
Because first patient in is not simply the end of
start-up. It is the first meaningful test of whether start-up was done well.
References
- International Council for Harmonisation. ICH
E8(R1): General Considerations for Clinical Studies. 2021.
- European Parliament and Council. Regulation (EU)
No 536/2014 on Clinical Trials on Medicinal Products for Human Use.
- European Medicines Agency. Clinical Trials
Information System and Clinical Trials Regulation guidance.
- International Council for Harmonisation. ICH
E6(R3): Guideline for Good Clinical Practice. 2025.
- Huang GD, Bull J, Johnston McKee K, et al.
Clinical trials recruitment planning: A proposed framework from the
Clinical Trials Transformation Initiative. Contemporary Clinical Trials.
2018;66:74–79. doi:10.1016/j.cct.2018.01.003.